Non-nucleoside reverse transcriptase inhibitors (NNRTIs) represent cornerstones of current regimens for treatment of human immunodeficiency virus type 1 (HIV-1) infections. However, NNRTIs usually suffer from low aqueous solubility and the emergence of resistant viral strains. In the present work, novel bicyclic NNRTIs derived from etravirine (ETV) and rilpivirine (RPV), bearing modified purine, tetrahydropteridine, and pyrimidodiazepine cores, were designed and prepared. Compounds 2, 4, and 6 carrying the acrylonitrile moiety displayed single-digit nanomolar activities against the wild-type (WT) virus (EC50 = 2.5, 2.7, and 3.0 nM, respectively), where the low nanomolar activity was retained against HXB2 (EC50 = 2.2-2.8 nM) and the K103N and Y181C mutated strains (fold change, 1.2-6.7×). Most importantly, compound 2 exhibited significantly improved phosphate-buffered saline solubility (10.4 μM) compared to ETV and RPV (≪1 μM). Additionally, the binding modes of compounds 2, 4, and 6 to the reverse transcriptase were studied by X-ray crystallography.

Department of Organic Chemistry Faculty of Science Charles University Hlavova 8 Prague 2 128 43 Czech Republic

Gilead Sciences Inc 333 Lakeside Drive Foster City California 94404 United States

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo nám 2 Prague 6 160 00 Czech Republic

Zobrazit více v PubMed

Hu W. S.; Hughes S. H. HIV-1 reverse transcription. Cold Spring Harbor Perspect. Med. 2012, 2, a006882.10.1101/cshperspect.a006882. PubMed DOI PMC

De Clercq E.; Li G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 2016, 29, 695–747. 10.1128/cmr.00102-15. PubMed DOI PMC

Arts E. J.; Hazuda D. J. HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspect. Med. 2012, 2, a007161.10.1101/cshperspect.a007161. PubMed DOI PMC

Balzarini J.; De Clercq E.. [25] Analysis of inhibition of retroviral reverse transcriptase. Methods in Enzymology; Academic Press, 1996; Vol. 275, pp 472–502. PubMed

Saag M. S.; Gandhi R. T.; Hoy J. F.; Landovitz R. J.; Thompson M. A.; Sax P. E.; Smith D. M.; Benson C. A.; Buchbinder S. P.; del Rio C.; Eron J. J. Jr.; Fätkenheuer G.; Günthard H. F.; Molina J. M.; Jacobsen D. M.; Volberding P. A. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 Recommendations of the international antiviral society-USA panel. JAMA, J. Am. Med. Assoc. 2020, 324, 1651–1669. 10.1001/jama.2020.17025. PubMed DOI PMC

Kohlstaedt L. A.; Wang J.; Friedman J. M.; Rice P. A.; Steitz T. A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783–1790. 10.1126/science.1377403. PubMed DOI

Tuske S.; Sarafianos S. G.; Clark A. D. Jr.; Ding J.; Naeger L. K.; White K. L.; Miller M. D.; Gibbs C. S.; Boyer P. L.; Clark P.; Wang G.; Gaffney B. L.; Jones R. A.; Jerina D. M.; Hughes S. H.; Arnold E. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 2004, 11, 469–474. 10.1038/nsmb760. PubMed DOI

Shafer R. W.; Vuitton D. A. Highly active antiretroviral therapy (Haart) for the treatment of infection with human immunodeficiency virus type 1. Biomed. Pharmacother. 1999, 53, 73–86. 10.1016/s0753-3322(99)80063-8. PubMed DOI

Usach I.; Melis V.; Peris J. E. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. Int. AIDS Soc. 2013, 16, 1–14. 10.7448/IAS.16.1.18567. PubMed DOI PMC

de Béthune M. P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antivir. Res. 2010, 85, 75–90. 10.1016/j.antiviral.2009.09.008. PubMed DOI

Apostolova N.; Funes H. A.; Blas-Garcia A.; Galindo M. J.; Alvarez A.; Esplugues J. V. Efavirenz and the CNS: What we already know and questions that need to be answered. J. Antimicrob. Chemother. 2015, 70, 2693–2708. 10.1093/jac/dkv183. PubMed DOI

Namasivayam V.; Vanangamudi M.; Kramer V. G.; Kurup S.; Zhan P.; Liu X.; Kongsted J.; Byrareddy S. N. The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. J. Med. Chem. 2019, 62, 4851–4883. 10.1021/acs.jmedchem.8b00843. PubMed DOI PMC

Côté B.; Burch J. D.; Asante-Appiah E.; Bayly C.; Bédard L.; Blouin M.; Campeau L. C.; Cauchon E.; Chan M.; Chefson A.; Coulombe N.; Cromlish W.; Debnath S.; Deschênes D.; Dupont-Gaudet K.; Falgueyret J. P.; Forget R.; Gagné S.; Gauvreau D.; Girardin M.; Guiral S.; Langlois E.; Li C. S.; Nguyen N.; Papp R.; Plamondon S.; Roy A.; Roy S.; Seliniotakis R.; St-Onge M.; Ouellet S.; Tawa P.; Truchon J. F.; Vacca J.; Wrona M.; Yan Y.; Ducharme Y. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett. 2014, 24, 917–922. 10.1016/j.bmcl.2013.12.070. PubMed DOI

Das K.; Bauman J. D.; Clark A. D. Jr.; Frenkel Y. V.; Lewi P. J.; Shatkin A. J.; Hughes S. H.; Arnold E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1466–1471. 10.1073/pnas.0711209105. PubMed DOI PMC

Lansdon E. B.; Brendza K. M.; Hung M.; Wang R.; Mukund S.; Jin D.; Birkus G.; Kutty N.; Liu X. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem. 2010, 53, 4295–4299. 10.1021/jm1002233. PubMed DOI

Rhee S. Y.; Kassaye S. G.; Barrow G.; Sundaramurthi J. C.; Jordan M. R.; Shafer R. W. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. J. Int. AIDS Soc. 2020, 23, e2561110.1002/jia2.25611. PubMed DOI PMC

Huang B.; Chen W.; Zhao T.; Li Z.; Jiang X.; Ginex T.; Vílchez D.; Luque F. J.; Kang D.; Gao P.; Zhang J.; Tian Y.; Daelemans D.; De Clercq E.; Pannecouque C.; Zhan P.; Liu X. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket: Discovery of potent diarylpyrimidine-typed HIV-1 NNRTIs against wild-type and E138K mutant virus with significantly improved water solubility and favorable safety profiles. J. Med. Chem. 2019, 62, 2083–2098. 10.1021/acs.jmedchem.8b01729. PubMed DOI

Kang D.; Zhang H.; Wang Z.; Zhao T.; Ginex T.; Luque F. J.; Yang Y.; Wu G.; Feng D.; Wei F.; Zhang J.; De Clercq E.; Pannecouque C.; Chen C. H.; Lee K.-H.; Murugan N. A.; Steitz T. A.; Zhan P.; Liu X. Identification of dihydrofuro[3,4-d]pyrimidine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors with promising antiviral activities and desirable physicochemical properties. J. Med. Chem. 2019, 62, 1484–1501. 10.1021/acs.jmedchem.8b01656. PubMed DOI PMC

Kang D. W.; Zhao T.; Wang Z.; Feng D.; Zhang H.; Huang B. S.; Wu G. C.; Wei F. J.; Zhou Z. X.; Jing L. L.; Zuo X. F.; Tian Y.; Poongavanam V.; Kongsted J.; De Clercq E.; Pannecouque C.; Zhan P.; Liu X. Y. Discovery of piperidine-substituted thiazolo 5,4-d pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Commun. Chem. 2019, 2, 74.10.1038/s42004-019-0174-8. DOI

Fraczek T.; Kaminski R.; Krakowiak A.; Naessens E.; Verhasselt B.; Paneth P. Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility. J. Enzym. Inhib. Med. Chem. 2018, 33, 9–16. 10.1080/14756366.2017.1387542. PubMed DOI PMC

Chen W. M.; Zhan P.; Daelemans D.; Yang J. P.; Huang B.; De Clercq E.; Pannecouque C.; Liu X. Y. Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. Eur. J. Med. Chem. 2016, 121, 352–363. 10.1016/j.ejmech.2016.05.054. PubMed DOI

Kang D. W.; Fang Z. J.; Li Z. Y.; Huang B. S.; Zhang H.; Lu X. Y.; Xu H. R.; Zhou Z. X.; Ding X.; Daelemans D.; De Clercq E.; Pannecouque C.; Zhan P.; Liu X. Y. Design, synthesis, and evaluation of thiophene 3,2-d pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J. Med. Chem. 2016, 59, 7991–8007. 10.1021/acs.jmedchem.6b00738. PubMed DOI

Liu N.; Wei L.; Huang L.; Yu F.; Zheng W. F.; Qin B. J.; Zhu D. Q.; Morris-Natschke S. L.; Jiang S. B.; Chen C. H.; Lee K. H.; Xie L. Novel HIV-1 non-nucleoside reverse transcriptase inhibitor agents: Optimization of diarylanilines with high potency against wild-type and rilpivirine-resistant E138K mutant virus. J. Med. Chem. 2016, 59, 3689–3704. 10.1021/acs.jmedchem.5b01827. PubMed DOI PMC

Frey K. M.; Puleo D. E.; Spasov K. A.; Bollini M.; Jorgensen W. L.; Anderson K. S. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J. Med. Chem. 2015, 58, 2737–2745. 10.1021/jm501908a. PubMed DOI PMC

Kang D.; Sun Y.; Feng D.; Gao S.; Wang Z.; Jing L.; Zhang T.; Jiang X.; Lin H.; De Clercq E.; Pannecouque C.; Zhan P.; Liu X. Development of novel dihydrofuro[3,4-d]pyrimidine derivatives as HIV-1 NNRTIs to overcome the highly resistant mutant strains F227L/V106A and K103N/Y181C. J. Med. Chem. 2022, 65, 2458–2470. 10.1021/acs.jmedchem.1c01885. PubMed DOI

Jin X.; Piao H.-R.; Pannecouque C.; De Clercq E.; Zhuang C.; Chen F.-E. Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. Eur. J. Med. Chem. 2021, 226, 113868.10.1016/j.ejmech.2021.113868. PubMed DOI

Zhang T.; Zhou Z.; Zalloum W. A.; Wang Z.; Fu Z.; Cherukupalli S.; Feng D.; Sun Y.; Gao S.; De Clercq E.; Pannecouque C.; Kang D.; Zhan P.; Liu X. Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. Bioorganic Chemistry 2021, 116, 105353.10.1016/j.bioorg.2021.105353. PubMed DOI

Huang B.; Ginex T.; Luque F. J.; Jiang X.; Gao P.; Zhang J.; Kang D.; Daelemans D.; De Clercq E.; Pannecouque C.; Zhan P.; Liu X. Structure-based design and discovery of pyridyl-bearing fused bicyclic HIV-1 inhibitors: Synthesis, biological characterization, and molecular modeling studies. J. Med. Chem. 2021, 64, 13604–13621. 10.1021/acs.jmedchem.1c00987. PubMed DOI

Ding L.; Pannecouque C.; De Clercq E.; Zhuang C.; Chen F.-E. Improving druggability of novel diarylpyrimidine NNRTIs by a fragment-based replacement strategy: From biphenyl-DAPYs to heteroaromatic-biphenyl-DAPYs. J. Med. Chem. 2021, 64, 10297–10311. 10.1021/acs.jmedchem.1c00708. PubMed DOI

Fu Z.; Zhang T.; Zhou Z.; Kang D.; Sun L.; Gao S.; Cherukupalli S.; De Clercq E.; Pannecouque C.; Liu X.; Zhan P. Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. Bioorg. Med. Chem. 2021, 42, 116239.10.1016/j.bmc.2021.116239. PubMed DOI

Gao P.; Song S.; Wang Z.; Sun L.; Zhang J.; Pannecouque C.; De Clercq E.; Zhan P.; Liu X. Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. Bioorg. Med. Chem. 2021, 40, 116195.10.1016/j.bmc.2021.116195. PubMed DOI

Jiang X.; Huang B.; Olotu F. A.; Li J.; Kang D.; Wang Z.; De Clercq E.; Soliman M. E. S.; Pannecouque C.; Liu X.; Zhan P. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. Eur. J. Med. Chem. 2021, 213, 113051.10.1016/j.ejmech.2020.113051. PubMed DOI

Feng D.; Zuo X.; Jing L.; Chen C.-H.; Olotu F. A.; Lin H.; Soliman M.; De Clercq E.; Pannecouque C.; Lee K.-H.; Kang D.; Liu X.; Zhan P. Design, synthesis, and evaluation of “dual-site”-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. Eur. J. Med. Chem. 2021, 211, 113063.10.1016/j.ejmech.2020.113063. PubMed DOI

Chen X.; Ding L.; Tao Y.; Pannecouque C.; De Clercq E.; Zhuang C.; Chen F.-E. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem. 2020, 202, 112549.10.1016/j.ejmech.2020.112549. PubMed DOI

Kang D.; Sun Y.; Murugan N. A.; Feng D.; Wei F.; Li J.; Jiang X.; De Clercq E.; Pannecouque C.; Zhan P.; Liu X. Structure–activity relationship exploration of NNIBP tolerant region I leads to potent HIV-1 NNRTIs. ACS Infect. Dis. 2020, 6, 2225–2234. 10.1021/acsinfecdis.0c00327. PubMed DOI

Yang Y.; Pannecouque C.; Clercq E. D.; Zhuang C.; Chen F.-E. Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1. Bioorg. Chem. 2020, 99, 103825.10.1016/j.bioorg.2020.103825. PubMed DOI

Sang Y.; Han S.; Pannecouque C.; De Clercq E.; Zhuang C.; Chen F. Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors. Eur. J. Med. Chem. 2019, 182, 111603.10.1016/j.ejmech.2019.111603. PubMed DOI

Wang Z.; Cherukupalli S.; Xie M.; Wang W.; Jiang X.; Jia R.; Pannecouque C.; De Clercq E.; Kang D.; Zhan P.; Liu X. Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 2022, 65, 3729–3757. 10.1021/acs.jmedchem.1c01758. PubMed DOI

Gu S.-X.; Xiao T.; Zhu Y.-Y.; Liu G.-Y.; Chen F.-E. Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket. Eur. J. Med. Chem. 2019, 174, 277–291. 10.1016/j.ejmech.2019.04.054. PubMed DOI

Das K.; Clark A. D. Jr.; Lewi P. J.; Heeres J.; de Jonge M. R.; Koymans L. M.; Vinkers H. M.; Daeyaert F.; Ludovici D. W.; Kukla M. J.; De Corte B.; Kavash R. W.; Ho C. Y.; Ye H.; Lichtenstein M. A.; Andries K.; Pauwels R.; de Béthune M. P.; Boyer P. L.; Clark P.; Hughes S. H.; Janssen P. A.; Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550–2560. 10.1021/jm030558s. PubMed DOI

Guillemont J.; Pasquier E.; Palandjian P.; Vernier D.; Gaurrand S.; Lewi P. J.; Heeres J.; de Jonge M. R.; Koymans L. M. H.; Daeyaert F. F. D.; Vinkers M. H.; Arnold E.; Das K.; Pauwels R.; Andries K.; de Béthune M. P.; Bettens E.; Hertogs K.; Wigerinck P.; Timmerman P.; Janssen P. A. J. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J. Med. Chem. 2005, 48, 2072–2079. 10.1021/jm040838n. PubMed DOI

Andrei G.; Carter K.; Janeba Z.; Sampath A.; Schang L. M.; Tarbet E. B.; Vere Hodge R. A.; Bray M.; Esté J. A. Highlights of the 30th International Conference on Antiviral Research. Antivir. Res. 2017, 145, 184–196. 10.1016/j.antiviral.2017.07.017. PubMed DOI PMC

Ge Y.; Jin Y.; Wang C.; Zhang J.; Tang Z.; Peng J.; Liu K.; Li Y.; Zhou Y.; Ma X. Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a N,9-Diphenyl-9H-purin-2-amine scaffold. ACS Med. Chem. Lett. 2016, 7, 1050–1055. 10.1021/acsmedchemlett.6b00235. PubMed DOI PMC

Vandecruys R. P. G.; Peeters J.; Brewster M. E.; Peeters J. J. P.; Brewster M. E. J. P.; Brewster M.. Pharmaceutical composition useful for medical prophylaxis, therapy or diagnosis, comprises basic or acidic drug compound, water soluble acid or base, respectively and surfactant. WO 2004050058-A2, 2004.

Banker P.; Boros E. E.; Dickerson S. H.; Kaldor I.; Koble C. S.; Martin M. T.; Sparks S. M.; Thomson S. A.; Bankeo P.; Boroseu E. Y.; Dikkeoseun S. H.; Kobeul S. E.; Mareutin M. T.; Seupakeuseu S. M.; Tomseun S. A.. Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof. WO 2009045830-A1, 2009.

Boon W. R.; Jones W. G. M.; Ramage G. R. 21. Pteridines. Part I. An unambiguous synthesis of 7 : 8-dihydro-6-hydroxypteridines. J. Chem. Soc. 1951, 96–102. 10.1039/jr9510000096. DOI

Li D. R.; Sun C. Y.; Su C.; Lin G. Q.; Zhou W. S. Toward the total synthesis of phorboxazole B: an efficient synthesis of the C20-C46 segment. Org. Lett. 2004, 6, 4261–4264. 10.1021/ol048275x. PubMed DOI

Roethle P. A.; McFadden R. M.; Yang H.; Hrvatin P.; Hui H.; Graupe M.; Gallagher B.; Chao J.; Hesselgesser J.; Duatschek P.; Zheng J.; Lu B.; Tumas D. B.; Perry J.; Halcomb R. L. Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis. J. Med. Chem. 2013, 56, 7324–7333. 10.1021/jm400815m. PubMed DOI

Kulkarni R.; Babaoglu K.; Lansdon E. B.; Rimsky L.; Van Eygen V.; Picchio G.; Svarovskaia E.; Miller M. D.; White K. L. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J. Acquir. Immune Defic. Syndr. 2012, 59, 47–54. 10.1097/qai.0b013e31823aca74. PubMed DOI

Gall M.; McCall J. M.; TenBrink R. E.; Von Voigtlander P. F.; Mohrland J. S. Arylformamidines with antinociceptive properties. J. Med. Chem. 1988, 31, 1816–1820. 10.1021/jm00117a023. PubMed DOI

Goldstein S. L.; McNelis E. Migrations in oxidations of mesidine. J. Org. Chem. 1984, 49, 1613–1620. 10.1021/jo00183a024. DOI

Li A. P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today 2001, 6, 357–366. 10.1016/s1359-6446(01)01712-3. PubMed DOI

Kabsch W. Xds. Acta Crystallogr. 2010, 66, 125–132. 10.1107/S0907444909047337. PubMed DOI PMC

Adams P. D.; Afonine P. V.; Bunkóczi G.; Chen V. B.; Davis I. W.; Echols N.; Headd J. J.; Hung L. W.; Kapral G. J.; Grosse-Kunstleve R. W.; McCoy A. J.; Moriarty N. W.; Oeffner R.; Read R. J.; Richardson D. C.; Richardson J. S.; Terwilliger T. C.; Zwart P. H. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. 2010, 66, 213–221. 10.1107/S0907444909052925. PubMed DOI PMC

Emsley P.; Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. 2004, 60, 2126–2132. 10.1107/S0907444904019158. PubMed DOI